Piper Jaffray Raises VRX Target To $41 From $35

Piper Jaffray is raising its target on Valeant Pharmaceutical VRX to $41, up from $35.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.